Spontaneous tumor lysis syndrome in diffuse large B-cell lymphoma patient as a cause of acute kidney injury

• Authors: Przemysław Kwiatkowski , Grzegorz Kade , Janusz Hałka
• Languages of publication: EN

Abstracts

EN

Idiopathic tumor lysis syndrome is a rare complication in the course of neoplastic disease. This condition requires an interdisciplinary therapeutic procedure. The presented case of spontaneous tumor lysis syndrome in the course of malignant large B-cell lymphoma describes an effective therapeutic approach in this type of cases.

Keywords

EN

acute kidney injury; interdisciplinary therapeutic procedure; spontaneous tumor lysis syndrome

Discipline

• MEDICINE: MEDICINE

• Publisher: Medical Education
• Journal: OncoReview
• Year: 2021
• Volume: 11
• Issue: 1
• Pages: 22-26

Contributors

author

Przemysław Kwiatkowski

• Department of Hematology, Warmian-Masurian Cancer Center of the Ministry of the Interior and Administration’s Hospital in Olsztyn, Poland

author

Grzegorz Kade

• Warmian-Masurian Cancer Center of the Ministry of the Interior and Administration’s Hospital in Olsztyn, Poland

author

Janusz Hałka

• Department of Hematology, Warmian-Masurian Cancer Center of the Ministry of the Interior and Administration’s Hospital in Olsztyn, Poland

References

• 1. Darmon M, Vincent F, Camous L et al. Tumour lysis syndrome and acute kidney injury in high-risk haematology patients in the rasburicase era. A prospective multicentre study from the Groupe de Recherche en Réanimation Respiratoire et Onco-Hématologique. Br J Haematol. 2013; 162(4): 489-97.
• 2. Lahoti A, Kantarjian H, Salahudeen AK et al. Predictors and outcome of acute kidney injury in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome. Cancer. 2010; 116(17): 4063-8.
• 3. Bedrna J, Polcák J. Actuary ureter closure after irradiation with x-rays for chronic leukemias. Medizinische Klinik. 1929; 25: 1700-1.
• 4. Cairo MS, Bishop M. Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol. 2004; 127(1): 3-11.
• 5. Crittenden DR, Ackerman GL. Hyperuricemic Acute Renal Failure in Disseminated Carcinoma. Arch Intern Med. 1977; 137(1): 97-9. http://doi.org/10.1001/archinte.1977.03630130065016.
• 6. Jasek AM, Day HJ. Acute spontaneous tumor lysis syndrome. Am J Hematol. 1994; 47: 129-31.
• 7. Lotfi M, Brandwein JM. Spontaneous acute tumor lysis syndrome in acute myeloid leukemia? A single case report with discussion of the literature. Leuk Lymphoma. 1998; 29: 625-8.
• 8. Kobayashi D, Wofford MM, McLean TW et al. Spontaneous tumor lysis syndrome in a child with T-cell acute lymphoblastic leukemia. Pediatr Blood Cancer. 2010; 54(5): 773-5. http://doi.org/10.1002/pbc.22384. PMID: 19998467.
• 9. Hsu HH, Huang CC. Acute spontaneous tumor lysis in anaplastic large T-cell lymphoma presenting with hyperuricemic acute renal failure. Int J Hematol. 2004; 79: 48-51.
• 10. Sile S, Wall BM. Acute renal failure secondary to spontaneous acute tumor lysis syndrome in myelofibrosis. Am J Kidney Dis. 2001; 38(4): E21.
• 11. Rampello E, Fricia T, Malaguarnera M. The management of tumor lysis syndrome. Nat Clin Pract Oncol. 2006; 3(8): 438-47. http://doi.org/10.1038/ncponc0581.
• 12. Larson RA. Tumor lysis syndrome: prevention and treatment. UpToDate. 2019; 1-22.
• 13. Trifilio S, Gordon L, Singhal S et al. Reduced-dose rasburicase (recombinant xanthine oxidase) in adult cancer patients with hyperuricemia. Bone Marrow Transplant. 2006; 37(11): 997-1001.
• 14. Wang LY, Shin LY, Chang H et al. Recombinant urate oxidase (rasburicase) for the prevention and treatment of tumor lysis syndrome in patients with hematologic malignancies. Acta Haematol. 2006; 115(1-2): 35-8.

• Document Type: article